Drugs · acquisition-cost intelligence
Methylphenidate Hydrochloride
· ingredient methylphenidate· METHYLPHENIDATE HYDROCHLORIDE 10 mg/1; METHYLPHENIDATE HYDROCHLORIDE 2.5 mg/1; METHYLPHENIDATE HYDROCHLORIDE 5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.91
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other methylphenidate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Methylin | $0.11303 | −$1.80 |
| Ritalin | $0.16210 | −$1.75 |
| Methylphenidate Hydrochloride | $0.49387 | −$1.42 |
| Methylphenidate Hydrochloride | $0.66777 | −$1.24 |
| CONCERTA | $0.69976 | −$1.21 |
| Methylphenidate Hydrochloride Extended-Release | $0.69976 | −$1.21 |
| methylphenidate hydrochloride CD | $1.49 | −$0.41540 |
| Methylphenidate Hydrochloride (LA) | $2.31 | +$0.40460 |
Medicare Part D coverage · CY2026
On 96 plan formularies · typical tier 4
Prior auth 32% · Step therapy 0% · Quantity limit 71% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.